Japanese nationwide cohort study also showed the rate of administration of anti‐tumor necrosis factor (TNF) increased from 0.3% in 2007 to 43% in 2017 among UC patients who underwent restorative proctocolectomy.13 Given the continuous emergence of biological therapies used more frequently in severe IBD, we are in a new era of biological therapy, including anti‐TNFα, anti‐interleukin (IL)‐12/23p40, anti‐integrin α4β7, and Janus kinase inhibitor, which will likely continue for some time. The gene discussed is TNF; the disease is inflammatory bowel disease.